Lexicon Pharmaceuticals Framtida tillväxt
Future kriterier kontrolleras 2/6
Lexicon Pharmaceuticals förväntas öka intäkter och intäkter med 29.2% respektive 27.5% per år. EPS förväntas tillväxt med 36.8% per år. Avkastningen på eget kapital förväntas bli -27.8% om 3 år.
Viktig information
29.2%
Tillväxttakt i vinsten
36.84%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 14.0% |
| Intäkternas tillväxttakt | 27.5% |
| Framtida avkastning på eget kapital | -27.78% |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 15 Apr 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
LXRX: Phase 3 Pain Program And Partnership Expectations Will Drive Repricing
Narrative Update Analysts have raised their price targets on Lexicon Pharmaceuticals to a range of about $2.30 to $6.00. They cite increased confidence in the pilavapadin program, particularly a higher assessed probability of success and expectations for a potential partnership on the Phase 3 ready asset.LXRX: Phase 3 Pain Program Progress And Partnership Expectations May Support Upside
Analysts have raised their average price targets for Lexicon Pharmaceuticals, with moves such as Citi's shift from $2.10 to $2.30 and H.C. Wainwright's adjustment from $4 to $6, citing a higher assumed probability of success for pilavapadin and progress on clinical and regulatory work that they see as reducing program risk. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals points to a generally constructive tone, with higher price targets linked to views on pilavapadin and the perceived risk profile of the pipeline.LXRX: Phase 3 Pain Program And Key Partnership Potential May Drive Upside
Analysts have nudged the fair value estimate for Lexicon Pharmaceuticals higher to $3.36 from $3.32, reflecting updated assumptions around revenue growth, profit margins and future P/E multiples following recent price target increases to $2.30 at one firm and $6 at another. Analyst Commentary Recent research updates offer a mixed picture on Lexicon Pharmaceuticals, with higher price targets tied closely to progress on its pipeline, particularly pilavapadin, and expectations around future execution.LXRX: Phase 3 Pain Program And Partnership Prospects Will Support Future Upside
Analysts have raised their price targets on Lexicon Pharmaceuticals, with one moving from $4 to $6, citing a higher assumed probability of success for pilavapadin and the potential for an important partnership on this Phase 3 ready program. Analyst Commentary Bullish Takeaways Bullish analysts see the higher assumed probability of success for pilavapadin, at 30% versus the prior 15%, as a key input to higher valuation for Lexicon, particularly as the program is described as Phase 3 ready.LXRX: Phase 3 Pain Program Progress Will Support Stronger Future Earnings Power
Analysts have raised their price target on Lexicon Pharmaceuticals by $0.20, citing updated assumptions around discount rates, profit margin expectations, and future P/E levels that refine their view of the stock's risk and earnings power. Analyst Commentary Analysts raising the price target by $0.20 are fine tuning their models rather than making a sweeping call, and their commentary gives you a sense of what they think could go right or wrong from here.LXRX: Phase 3 Pain Program Progress Will Support Higher Future Earnings Power
Analysts have nudged their price target for Lexicon Pharmaceuticals higher, with fair value moving from US$2.75 to US$2.92 as they factor in updated views on discount rates, revenue growth, profit margins and future P/E multiples. Analyst Commentary Analysts updating their models around Lexicon Pharmaceuticals are using the new fair value estimate of US$2.92 as a reference point, linking it to assumptions on discount rates, revenue trajectories, margins and future P/E levels.Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
Jan 22Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up
Jan 22
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Dec 18Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%
Oct 02Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Lexicon Pharmaceuticals' price target was revised down to $2.75 as analysts weigh mixed signals: strong Q2 results and management confidence against heightened reliance on positive upcoming PROGRESS trial data as a near-term share catalyst. Analyst Commentary Upward price target revision follows recent Q2 results exceeding expectations.Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Despite a sharp downgrade in revenue growth forecasts, Lexicon Pharmaceuticals’ consensus analyst price target has increased notably, supported by a lower future P/E ratio and now stands at $3.05. What's in the News Post-hoc analysis of clinical data showed sotagliflozin reduced hypoglycemia events without increased risk across kidney function subgroups in type 1 diabetes patients using optimized insulin therapy.There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump
Jul 28Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
Jun 13Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
May 19Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates
May 17
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Mar 28Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%
Mar 26Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Oct 16Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Aug 08Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Aug 03Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
May 28Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 69 | -62 | N/A | -107 | 5 |
| 12/31/2027 | 20 | -91 | N/A | -92 | 5 |
| 12/31/2026 | 34 | -72 | N/A | -53 | 5 |
| 12/31/2025 | 50 | -50 | -68 | -68 | N/A |
| 9/30/2025 | 71 | -69 | -73 | -72 | N/A |
| 6/30/2025 | 58 | -121 | -103 | -102 | N/A |
| 3/31/2025 | 31 | -177 | -168 | -167 | N/A |
| 12/31/2024 | 31 | -200 | -180 | -179 | N/A |
| 9/30/2024 | 5 | -216 | -208 | -208 | N/A |
| 6/30/2024 | 4 | -202 | -196 | -196 | N/A |
| 3/31/2024 | 2 | -194 | -186 | -185 | N/A |
| 12/31/2023 | 1 | -177 | -162 | -162 | N/A |
| 9/30/2023 | 1 | -158 | -135 | -133 | N/A |
| 6/30/2023 | 0 | -131 | -112 | -111 | N/A |
| 3/31/2023 | 0 | -110 | -99 | -97 | N/A |
| 12/31/2022 | 0 | -102 | -90 | -89 | N/A |
| 9/30/2022 | 0 | -97 | -90 | -90 | N/A |
| 6/30/2022 | 0 | -97 | -88 | -88 | N/A |
| 3/31/2022 | 0 | -90 | -87 | -85 | N/A |
| 12/31/2021 | 0 | -88 | -88 | -87 | N/A |
| 9/30/2021 | 0 | -68 | -100 | -98 | N/A |
| 6/30/2021 | 7 | 38 | 38 | -122 | N/A |
| 3/31/2021 | 16 | -13 | 14 | -146 | N/A |
| 12/31/2020 | 24 | -59 | 17 | -143 | N/A |
| 9/30/2020 | 33 | -104 | 27 | -133 | N/A |
| 6/30/2020 | 320 | 39 | 98 | 98 | N/A |
| 3/31/2020 | 321 | 85 | 117 | 117 | N/A |
| 12/31/2019 | 322 | 130 | 114 | 114 | N/A |
| 9/30/2019 | 330 | 164 | N/A | 111 | N/A |
| 6/30/2019 | 43 | -89 | N/A | -102 | N/A |
| 3/31/2019 | 47 | -101 | N/A | -127 | N/A |
| 12/31/2018 | 63 | -121 | N/A | -149 | N/A |
| 9/30/2018 | 81 | -126 | N/A | -155 | N/A |
| 6/30/2018 | 101 | -129 | N/A | -167 | N/A |
| 3/31/2018 | 99 | -130 | N/A | -147 | N/A |
| 12/31/2017 | 92 | -123 | N/A | -185 | N/A |
| 9/30/2017 | 80 | -133 | N/A | -200 | N/A |
| 6/30/2017 | 81 | -138 | N/A | -202 | N/A |
| 3/31/2017 | 89 | -141 | N/A | -217 | N/A |
| 12/31/2016 | 79 | -131 | N/A | -176 | N/A |
| 9/30/2016 | 188 | -22 | N/A | 139 | N/A |
| 6/30/2016 | 160 | -22 | N/A | 149 | N/A |
| 3/31/2016 | 141 | -11 | N/A | 165 | N/A |
| 12/31/2015 | 130 | -5 | N/A | 185 | N/A |
| 9/30/2015 | 24 | -94 | N/A | -86 | N/A |
| 6/30/2015 | 24 | -100 | N/A | -81 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: LXRX förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: LXRX förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: LXRX förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: LXRX s intäkter ( 27.5% per år) förväntas växa snabbare än US marknaden ( 11.2% per år).
Hög tillväxtintäkter: LXRX s intäkter ( 27.5% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: LXRX förväntas bli olönsam om 3 år.
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/04 12:44 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Lexicon Pharmaceuticals, Inc. bevakas av 12 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Andrew Tsai | Jefferies LLC |